Back to Clinical Trials
Phase 2Recruiting

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Sponsored by Celgene

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

Where this study is enrolling (12)

  • Alabama Neurology Associates

    Birmingham, Alabama

    Call 205-803-2210

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Perseverance Research Center,LLC

    Scottsdale, Arizona

    Call 602-258-3368

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Aqualane Clinical Research

    Naples, Florida

    Call 239-529-6780

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • USF Health

    Tampa, Florida

    Call 813-974-6378

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Kansas Medical Center

    Kansas City, Kansas

    Call 913-588-6980

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Show all 12 locations

  • Neurology Center of New England

    Foxborough, Massachusetts

    Call 781-551-5812

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Washington University School of Medicine

    St Louis, Missouri

    Call 314-362-3293

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Riverside Methodist Hospital

    Columbus, Ohio

    Call 614-566-1255

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

    Call 412-427-7087

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Thomas Jefferson University, Jefferson Headache Center

    Philadelphia, Pennsylvania

    Call 215-955-6871

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • Hope Neurology

    Knoxville, Tennessee

    Call 865-218-6222

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

  • EvergreenHealth Medical Center

    Kirkland, Washington

    Call 425-899-5385

    This research site can be reached directly by phone. Call to ask about this study.

    Create a free account to get updates on similar Clinical Trials for your conditions.

Who can participate

Inclusion criteria

  • ✓Participants must have a multiple sclerosis (MS) diagnosis.
  • ✓Participants must have a history of spasticity due to MS for at least 6 months prior to Visit 1.
  • ✓Participants must have a Modified Ashworth Scale (mAS) score ≥2 in each of 2 muscle groups (at least one muscle group in the leg, excluding ankle plantar flexors) at Visit 1.
  • ✓Participants must have an Expanded Disability Status Scale (EDSS) score 3.0-6.5 at Visit 1.

Exclusion criteria

  • ✕Participants must not have any concomitant disease or disorder that has symptoms of spasticity or that may influence the participant's level of spasticity.
  • ✕Participants must not have an acute MS exacerbation/relapse requiring treatment or alteration in disease modifying drug dose within 3 months of Visit 1 or Visit 2.
  • ✕Participants must not have a history of any substance abuse disorder as defined in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) Diagnostic Criteria for Drug and Alcohol Abuse.
  • ✕Participants must not be currently taking a medication for spasticity that cannot be discontinued and washed out by Visit 2.
  • ✕Participants must not have used FAAH/MAGL inhibitor medication or any cannabinoid-related products (including cannabis, cannabidiol (CBD), or tetrahydrocannabinol (THC)) within 30 days prior to Visit 1.
  • ✕Other protocol-defined Inclusion/Exclusion criteria apply.

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.